home / stock / arfxf / arfxf news

ARFXF News and Press, Amorfix Life Sciences Ltd From 01/29/20

Stock Information
Company Name: Amorfix Life Sciences Ltd
Stock Symbol: ARFXF
Market: OTC
Website: promisneurosciences.com
Menu
ARFXF ARFXF Quote ARFXF Short ARFXF News ARFXF Articles ARFXF Message Board
Get ARFXF Alerts

News, Short Squeeze, Breakout and More Instantly...
ARFXF - ProMIS Neurosciences Data for Alzheimer's Disease Program Targeting Tau Accepted for Presentation at Tau2020

TORONTO and CAMBRIDGE, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...
ARFXF - ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advisory Board

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 15, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerati...

ARFXF - ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum

TORONTO and CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...

ARFXF - ProMIS Neurosciences issues Chairman's Update detailing positive outlook for Alzheimer's disease therapy, pipeline in 2020

TORONTO and CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...
ARFXF - ProMIS Neurosciences Completes Second Closing of Private Placement

  NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Dec. 31, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (“ ProMIS ” or the “ Company ”) (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on th...

ARFXF - ProMIS Neurosciences' Alzheimer's disease program takes on renewed significance following positive aducanumab news

TORONTO and CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...

ARFXF - Aducanumab is good; next generation Alzheimer's disease therapies will be better

TORONTO and CAMBRIDGE, Mass., Dec. 05, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseas...
ARFXF - ProMIS Neurosciences Completes First Closing of Private Placement

ProMIS Neurosciences Completes First Closing of Private Placement Canada NewsWire TORONTO, Nov. 18, 2019 /NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO , Nov. 18, 2019 /CNW/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTC...

ARFXF - Promis Neurosciences reports Q3 results

Promis Neurosciences ( OTCQB:ARFXF ): Q3 net loss of $1.64M. Press Release More news on: ProMIS Neurosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,

ARFXF - ProMIS Neurosciences Announces Third Quarter 2019 Results

ProMIS Neurosciences Announces Third Quarter 2019 Results Canada NewsWire TORONTO and CAMBRIDGE, MA, Nov. 14, 2019 Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease TORONTO and CA...
Previous 10 Next 10